VDPHL01 QD + Placebo + VDPHL01 BID + Placebo
Phase 3Recruiting 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Androgenetic Alopecia (AGA)
Conditions
Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA, Female Androgenetic Alopecia, Hair Loss
Trial Timeline
Jul 25, 2025 → Jan 1, 2028
NCT ID
NCT07146022About VDPHL01 QD + Placebo + VDPHL01 BID + Placebo
VDPHL01 QD + Placebo + VDPHL01 BID + Placebo is a phase 3 stage product being developed by Veradermics for Androgenetic Alopecia (AGA). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07146022. Target conditions include Androgenetic Alopecia (AGA), Androgenetic Alopecia, AGA.
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07146022 | Phase 3 | Recruiting |
Competing Products
12 competing products in Androgenetic Alopecia (AGA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| minoxidil | Johnson & Johnson | Phase 3 | 77 |
| Minoxidil + vehicle of 5% Minoxidil topical foam | Johnson & Johnson | Phase 2 | 52 |
| 5% Minoxidil Topical Foam + Vehicle Topical Foam | Johnson & Johnson | Phase 3 | 77 |
| Cyproterone Acetate (Androcur, BAY94-8367) | Bayer | Pre-clinical | 20 |
| Clascoterone 5% solution + Vehicle solution | ICON plc. | Phase 3 | 74 |
| Clascoterone 5% solution + Vehicle solution | ICON plc. | Phase 3 | 74 |
| VDPHL01 | Veradermics | Phase 2 | 47 |
| VDPHL01 + Placebo | Veradermics | Phase 2/3 | 60 |
| VDPHL01 + Placebo | Veradermics | Phase 3 | 72 |
| MK0906, finasteride / Duration of Treatment : 48 Weeks + Comparator : placebo (unspecified) / Duration of Treatment : 48 Weeks | Organon | Phase 3 | 72 |
| ABS-201 IV Single Dose + Placebo IV + ABS-201 SC Multiple Doses + Placebo SC Injection | AbSci | Phase 1/2 | 33 |
| ATI-50002 | Aclaris Therapeutics | Phase 2 | 44 |